Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress
3.9.2019 15:14:00 EEST | Business Wire | Press release
Incyte (Nasdaq:INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and efficacy data in patients with FGFR2 fusions or rearrangements, as well as genomic profiling and correlations with clinical outcomes will be presented. Results from the Phase 1 study of INCB001158, an arginase inhibitor being developed with Calithera Biosciences, alone and in combination with pembrolizumab as a treatment for advanced or metastatic solid tumors, will also be presented.
“Incyte is committed to advancing treatments that have the potential to address areas of high unmet need and we look forward to sharing data on our investigational therapies with the oncology community at ESMO 2019,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data from the Phase 2 FIGHT-202 study assessing pemigatinib as a potential treatment for cholangiocarcinoma are encouraging and may represent an important step forward for patients in urgent need of effective treatment options.”
Abstracts will be available on the ESMO Congress website at https://www.esmo.org/Conferences/ESMO-Congress-2019.
Oral Presentations:
FIGHT-202: a Phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) (Abstract #2550, proffered paper session)
- Friday, September 27, 2019 from 3:00 p.m. CEST to 3:15 p.m. CEST (9 a.m. ET to 9:15 a.m. ET) in Madrid Auditorium (Hall 2)
Phase 1 study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (Adv/Met) solid tumors (Abstract #1621, oral abstract session)
- Sunday, September 29, 2019 from 4:54 p.m. CEST to 5:06 p.m. CEST (10:54 a.m. ET to 11:06 a.m. ET) in Malaga Auditorium (Hall 5)
Poster Details:
Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the FIGHT-202 trial (Abstract #2078, poster session)
- Sunday, September 29, 2019 from 12:00 p.m. CEST to 1:00 p.m. CEST (6:00 a.m. ET to 7:00 a.m. ET) in Poster Area (Hall 4)
Full session details and data presentation listings for ESMO 2019 can be found at: https://cslide.ctimeetingtech.com/esmo2019/attendee.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s ongoing clinical development programs for pemigatinib and an arginase inhibitor as monotherapy and in combination with pembrolizumab and the potential of such programs, including the potential for pemigatinib to treat cholangiocarcinoma, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2019. The Company disclaims any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005491/en/
Contact information
Incyte Contacts
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas: Delivering on Our Commitments With Higher Sequential Organic Growth in Q2 and Continuous Margin Improvements29.7.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): H1 2026 key figures1 › Revenue of EUR 3,258.4 million in H1 2026, up 2.1% year-on-year and up 5.0% organically (with a sequential improvement in Q2 2026 at 5.5% organic growth), › Adjusted operating profit of EUR 506.5 million, up 3.1% versus EUR 491.5 million in H1 2025, representing an adjusted operating margin of 15.5%, up 15 basis points year-on-year and up 29 basis points at constant currency, › Operating profit of EUR 430.8 million, down 16.0% versus EUR 513.1 million in H1 20252, › Adjusted net profit of EUR 303.8 million, up 3.9% versus EUR 292.4 million in H1 2025, › Adjusted EPS stood at EUR 0.68 in H1 2026, with a 4.8% increase on a reported basis versus H1 2025 (EUR 0.65 per share) and 9.8% at constant currency, › Attributable net profit of EUR 237.9 million, down 26.2% versus EUR 322.3 in H1 2025, › Free Cash Flow of EUR 157.7 million, up 3.2% organically, and down 6.1% year-on-year due to forex evolutions, › Adjusted net debt/EBITDA ratio stoo
IFF Declares Dividend for Third Quarter 202628.7.2026 23:15:00 EEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 9, 2026 to shareholders of record as of September 18, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260728319763/en/
Logitech Announces Q1 Fiscal Year 2027 Results28.7.2026 23:06:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the first quarter of Fiscal Year 2027. Sales were $1.23 billion, up 7 percent in US dollars and 5 percent in constant currency, compared to Q1 of the prior year. GAAP gross margin was 49.5 percent, up 780 basis points, compared to Q1 of the prior year. Non-GAAP gross margin was 49.8 percent, up 770 basis points, compared to Q1 of the prior year. These numbers include $61 million in tariff refunds. GAAP operating income was $259 million, up 60 percent, compared to Q1 of the prior year. Non-GAAP operating income was $290 million, up 44 percent, compared to Q1 of the prior year. These numbers include $61 million in tariff refunds. GAAP earnings per share (EPS) was $1.63, up 66 percent compared to Q1 of the prior year. Non-GAAP EPS was $1.85, up 47 percent compared to Q1 of the prior year. Cash flow from operations was $167 million. The qua
Nexo Reaffirms EU Compliance28.7.2026 17:00:00 EEST | Press release
Nexo, a leading digital assets wealth platform, today reaffirmed product compliance across the European Economic Area (EEA), achieved ahead of MiCAR’s entry into force. The company operates with a local setup through two MiCAR-licensed partners bringing technical depth and operational maturity to Nexo's client-facing platform in the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728038475/en/ Nexo's setup pairs its global wealth platform with dedicated, licensed European infrastructure — splitting custody and brokerage across two regulated partners: Tangany, licensed under MiCAR, provides institutional-grade custody infrastructure for digital assets. Meanwhile, DLT Finance, licensed under MiCAR and authorized under MiFID II, provides brokerage infrastructure for digital assets and financial instruments. Together, these partnerships pair Nexo’s global wealth platform with infrastructure specifically built for Europ
Interactive Brokers Opens AI Connectivity to Any Tool Built on the MCP Standard28.7.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that clients can now connect their accounts to nearly any AI tool they already use. Previously limited to the certified marketplaces for ChatGPT, Claude, and Grok, clients can now also connect from a growing range of tools that support the Model Context Protocol (MCP), including Claude Code, Cursor, Perplexity, and Windsurf. MCP has become the common standard for connecting AI applications to outside services. Interactive Brokers' AI Integration has been built on MCP since launch, and clients can now connect from any MCP-compatible tool in addition to the certified marketplaces. “Interactive Brokers has long offered open APIs that let clients connect their accounts to the tools and systems they choose,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “Supporting AI tools built on the Model Context Protocol (MCP) is a natural extension of that philosophy. It gives clients the flexibility to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom